| __timestamp | Alnylam Pharmaceuticals, Inc. | Bausch Health Companies Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 2026300000 |
| Thursday, January 1, 2015 | 60610000 | 2682700000 |
| Friday, January 1, 2016 | 89354000 | 2810000000 |
| Sunday, January 1, 2017 | 199365000 | 2582000000 |
| Monday, January 1, 2018 | 382359000 | 2473000000 |
| Tuesday, January 1, 2019 | 479005000 | 2554000000 |
| Wednesday, January 1, 2020 | 588420000 | 2367000000 |
| Friday, January 1, 2021 | 620639000 | 2624000000 |
| Saturday, January 1, 2022 | 770658000 | 2625000000 |
| Sunday, January 1, 2023 | 795646000 | 2917000000 |
| Monday, January 1, 2024 | 975526000 |
Unveiling the hidden dimensions of data
In the competitive landscape of pharmaceuticals, effective cost management is crucial. Alnylam Pharmaceuticals, Inc. and Bausch Health Companies Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Alnylam's SG&A expenses surged by approximately 1,700%, reflecting its aggressive growth and expansion strategy. In contrast, Bausch Health maintained a more stable trajectory, with expenses fluctuating around a 44% range, peaking in 2023. This divergence highlights Alnylam's investment in scaling operations, while Bausch Health focuses on optimizing existing resources. Understanding these trends provides valuable insights into each company's strategic priorities and financial health. As the industry evolves, monitoring such financial metrics will be key to predicting future market leaders.
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
Alnylam Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.
Biogen Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Bausch Health Companies Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Bausch Health Companies Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
MorphoSys AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Bausch Health Companies Inc. vs Merus N.V.: SG&A Expense Trends
Comparing SG&A Expenses: Bausch Health Companies Inc. vs Agios Pharmaceuticals, Inc. Trends and Insights